Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical isolates from Switzerland.

Publication

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical isolates from Switzerland.

Journal Paper/Review - Apr 25, 2023

Babouee Flury Baharak, Bösch Anja, Gisler Valentin, Egli Adrian, Seiffert Salome N, Nolte Oliver, Findlay Jacqueline

Citation

Babouee Flury B, Bösch A, Gisler V, Egli A, Seiffert S, Nolte O, Findlay J. Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical isolates from Switzerland. Front Cell Infect Microbiol 2023; 13:1098944.

Type

Journal Paper/Review (English)

Journal

Front Cell Infect Microbiol 2023; 13

Publication Date

Apr 25, 2023

Issn Electronic

2235-2988

Pages

1098944

Brief description/objective

Increasing reports of multidrug resistance (MDR) in clinical have led to a necessity for new antimicrobials. Ceftazidime-avibactam (CZA) is indicated for use against MDR across a broad range of infection types and particularly those that are carbapenem resistant. This study sought to determine the molecular mechanisms of CZA and imipenem (IPM)-resistance in clinical isolates obtained from Swiss hospitals.